Paliperidone Extended-Release Tablets Suppliers & Bulk Manufacturers
Available Forms: Extended-Release Tablets
Available Strengths: 1.5 mg, 3 mg, 6 mg, 9 mg
Reference Brands: Invega®(US & EU)
Category: Antipsychotropic Drugs
Paliperidone Extended-Release Tablets is available in Extended-Release Tablets and strengths such as 1.5 mg, 3 mg, 6 mg, 9 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Paliperidone Extended-Release Tablets is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Paliperidone Extended-Release Tablets can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Paliperidone extended-release tablets (brand name: Invega) are FDA-approved in the United States for the treatment of schizophrenia and schizoaffective disorder in adults. In the European Union, they are authorized under the centralized procedure for schizophrenia. Regulatory requirements include GMP-compliant manufacturing, osmotic-controlled release oral delivery system (OROS) data, and comprehensive clinical efficacy and safety studies. The product labeling in the U.S. includes a boxed warning for increased mortality in elderly patients with dementia-related psychosis. EU authorization also mandates Risk Management Plans (RMPs) and post-marketing safety monitoring. To explore dossier-ready Paliperidone ER tablets, visit Pharmatradz.com.
Frequently Asked Questions
Related Products
Risperidone Long-Acting Injection
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes
Form: Long-Acting Injection
Reference Brands: Risperdal Consta(US &EU)
View Details
Zuclopenthixol Ong-Acting Im Injection (Depot)
Strength: 200 mg/mL, 500 mg/mL
Form: Long-acting IM Injection (Depot)
Reference Brands: Clopixol Depot®(US)
View Details
Zuclopenthixol Short-Acting Intramuscular Injection
Strength: 50 mg/mL
Form: Short-acting Intramuscular Injection
Reference Brands: Clopixol-Acuphase®
View Details
Zuclopenthixol Tablets
Strength: 10 mg, 25 mg, 40 mg
Form: Oral Tablets
Reference Brands: Clopixol®(EU)
View DetailsQuick Response Guaranteed | Verified Suppliers